Table 1.
Approved indications of brentuximab vedotin, nivolumab, and pembrolizumab according to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).
| EMA: European Medicines Agency | FDA: US Food and Drug Administration |
|---|---|
| Brentuximab vedotin | |
| 1. rr-cHL, CD30+ following | 1. rr-cHL after failure of |
| 1.1 autoSCT or | 1.1 autoSCT or |
| 1.2 ≥2 prior therapies, when autoSCT or multi-agent chemotherapy is not a treatment option | 1.2 ≥2 prior multi-agent chemotherapy regimens in patients who are not autoSCT candidates |
| 2. CD30+ HL at increased risk of relapse or progression following autoSCT | 2. cHL at high risk of relapse or progression, as post autoSCT consolidation |
| 3. Adult patients with previously untreated stage IV, CD30+ cHL, in combination with AVD * | 3. Previously untreated stage III/IV cHL, in combination with AVD * |
| Nivolumab | |
| 1. As monotherapy in adult patients with rr-cHL after autoSCT and treatment with BV | 1. Adult patients with cHL that have relapsed or progressed after |
| 1.1 autoSCT and BV or | |
| 1.2 ≥3 lines of systemic therapy that included autoSCT | |
| Pembrolizumab | |
| 1. As monotherapy in adult patients with rr-cHL | 1. Adult and pediatric patients with refractory cHL, or who have relapsed after ≥3 prior lines of therapy |
| 1.1 who have failed autoSCT and BV, or | |
| 1.2 who are transplant-ineligible and have failed BV | |
HL = Hodgkin lymphoma; cHL = classical Hodgkin lymphoma; rr-cHL = relapsed/refractory classical Hodgkin lymphoma; autoSCT = autologous stem cell transplantation; BV = brentuximab vedotin. * AVD = combination of doxorubicin, vinblastine, and dacarbazine.